YC Biotech and New Keelung Community Health Care Group announce successful signing event at Bambino Italian Restaurant to promote the application of EG BioMed’s DNA methylation cancer biomarker test in breast cancer.
This innovative testing technology has garnered attention in the industry for its “simple, fast, and accurate” features. The breast cancer detection sensitivity and specificity of this technology exceed 90%, with a simple blood draw required for the test. The DNA methylation blood test offers a clear advantage over other current breast cancer detection methods available on the market. YC Biotech stated, “This is a significant breakthrough, enabling more women to benefit from early and precise breast cancer diagnosis, which helps improve treatment outcomes and survival rates.”
In addition, YC Biotech revealed that the test technology has been officially submitted to the U.S. FDA for certification review, and it is expected to receive certification soon. This will increase the technology’s recognition and application in the international medical market. The signing event successfully concluded with both parties’ collaborative efforts, and the cooperation between YC Biotech and New Keelung Community Health Care Group is considered an important contribution to advancing Taiwan’s healthcare industry.